Mirati Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Mirati Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2021 to Q3 2023.
  • Mirati Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2023 was $14.7M.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $14.7M Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $10.5M Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $6.23M Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $865K +$865K Dec 31, 2022 10-Q 2023-11-06
Q4 2021 $0 Dec 31, 2021 10-K 2023-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.